L1 Global Manager Pty Ltd Takes $2.08 Million Position in Drugs Made In America Acquisition Corp. $DMAA

L1 Global Manager Pty Ltd purchased a new stake in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $2,075,000. Drugs Made In America Acquisition accounts for about 1.4% of L1 Global Manager Pty Ltd’s holdings, making the stock its 16th largest position.

Other large investors have also modified their holdings of the company. Sandia Investment Management LP acquired a new position in shares of Drugs Made In America Acquisition in the 3rd quarter valued at $161,000. Quarry LP acquired a new position in shares of Drugs Made In America Acquisition in the 3rd quarter valued at $161,000. Shaolin Capital Management LLC acquired a new position in shares of Drugs Made In America Acquisition in the 2nd quarter valued at $1,020,000. JPMorgan Chase & Co. acquired a new position in shares of Drugs Made In America Acquisition in the 3rd quarter valued at $1,024,000. Finally, Radcliffe Capital Management L.P. acquired a new position in shares of Drugs Made In America Acquisition in the 2nd quarter valued at $1,293,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Drugs Made In America Acquisition Price Performance

DMAA opened at $10.61 on Friday. Drugs Made In America Acquisition Corp. has a 12 month low of $10.17 and a 12 month high of $10.62. The business has a fifty day moving average price of $10.57 and a 200 day moving average price of $10.47.

Drugs Made In America Acquisition (NASDAQ:DMAA) last released its earnings results on Thursday, May 14th. The company reported $0.06 EPS for the quarter.

Drugs Made In America Acquisition Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.